Francisco Cuellar
University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francisco Cuellar.
Journal of Medical Genetics | 2006
Alisa M. Goldstein; May Chan; Mark Harland; Nicholas K. Hayward; Florence Demenais; D. Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarrà; William Bruno; Donato Calista; Lisa A. Cannon Albright; Valérie Chaudru; Agnès Chompret; Francisco Cuellar; David E. Elder; Paola Ghiorzo; Elizabeth M. Gillanders; Nelleke A. Gruis; Johan Hansson; David Hogg; Elizabeth A. Holland; Peter A. Kanetsky; Richard F. Kefford; Maria Teresa Landi; Julie Lang; Sancy A. Leachman; Rona M. MacKie; Veronica Magnusson; Graham J. Mann
Background: The major factors individually reported to be associated with an increased frequency of CDKN2A mutations are increased number of patients with melanoma in a family, early age at melanoma diagnosis, and family members with multiple primary melanomas (MPM) or pancreatic cancer. Methods: These four features were examined in 385 families with ⩾3 patients with melanoma pooled by 17 GenoMEL groups, and these attributes were compared across continents. Results: Overall, 39% of families had CDKN2A mutations ranging from 20% (32/162) in Australia to 45% (29/65) in North America to 57% (89/157) in Europe. All four features in each group, except pancreatic cancer in Australia (p = 0.38), individually showed significant associations with CDKN2A mutations, but the effects varied widely across continents. Multivariate examination also showed different predictors of mutation risk across continents. In Australian families, ⩾2 patients with MPM, median age at melanoma diagnosis ⩽40 years and ⩾6 patients with melanoma in a family jointly predicted the mutation risk. In European families, all four factors concurrently predicted the risk, but with less stringent criteria than in Australia. In North American families, only ⩾1 patient with MPM and age at diagnosis ⩽40 years simultaneously predicted the mutation risk. Conclusions: The variation in CDKN2A mutations for the four features across continents is consistent with the lower melanoma incidence rates in Europe and higher rates of sporadic melanoma in Australia. The lack of a pancreatic cancer–CDKN2A mutation relationship in Australia probably reflects the divergent spectrum of mutations in families from Australia versus those from North America and Europe. GenoMEL is exploring candidate host, genetic and/or environmental risk factors to better understand the variation observed.
Journal of Clinical Oncology | 2005
Susana Puig; Josep Malvehy; Celia Badenas; Anna Ruiz; Dolores Jiménez; Francisco Cuellar; Antoni Azón; Urbá Gonzàlez; Teresa Castel; Antoni Campoy; Josep Eugeni Herrero; Rosa M. Martí; Joan Brunet-Vidal; Montserrat Milà
PURPOSE We have studied a consecutive case series of patients with multiple primary melanoma (MPM) for the involvement of the melanoma susceptibility loci CDKN2A and CDK4. PATIENTS AND METHODS One hundred four MPM patients (81 patients with two primary melanomas, 14 with three, five with four, one with five, two with six, and one with seven) were included. RESULTS Seven different CDKN2A germline mutations were identified in 17 patients (16.3%). In total, we identified 15 CDKN2A exon 2, one exon 1alpha missense mutation, and one exon 1beta frameshift mutation. The age of onset was significantly lower and the number of primary melanomas higher in patients with mutations. CDKN2A mutations were more frequent in patients with familial history of melanoma (35.5%) compared with patients without (8.2%), with a relative risk (RR) of 4.32 (95% CI, 1.76 to 10.64; P = .001), and in patients with more than two melanomas (39.1%) compared with patients with only two melanomas (10%) with an RR of 3.29 (95% CI, 1.7 to 6.3; P = .002). The A148T polymorphism was more frequent in patients with MPMs than in the control population (P = .05). A variant of uncertain significance, A127S, was also detected in one patient. No CDK4 mutations were identified, suggesting that it has a low impact in susceptibility to MPM. CONCLUSION MPM patients are good candidates for CDKN2A mutational screening. These patients and some of their siblings should be included in a program of specific follow-up with total body photography and digital dermoscopy, which will result in the early detection of melanoma in this subset of high-risk patients and improve phenotypic characterization.
Cancer Epidemiology, Biomarkers & Prevention | 2010
Richard Bränström; Y.M. Chang; Paul Affleck; Aad Tibben; Lisa G. Aspinwall; Esther Azizi; Orna Baron-Epel; Wilma Bergman; William Bruno; May Chan; Francisco Cuellar; Tadeusz Dębniak; Dace Pjanova; Sławomir Ertmański; Adina Figl; Melinda Gonzalez; Nicholas K. Hayward; Marko Hocevar; Peter A. Kanetsky; Sancy A. Leachman; Olita Heisele; Jane M. Palmer; Barbara Peric; Susana Puig; Dirk Schadendorf; Nelleke A. Gruis; Julia Newton-Bishop; Yvonne Brandberg
Background: The incidence of melanoma continues to increase in many countries, and primary prevention of melanoma includes avoidance of sunburn as well as adequate sun protection behavior. The aim of this study was to examine the prevalence of self-reported sun protection behaviors and sunburn in users of the Internet, and to identify the demographic, clinical, and attitudinal/motivational correlates of sun protection behaviors. Methods: Self-report data were gathered on behalf of the GenoMEL consortium using an online survey available in 10 different languages, and 8,178 individuals successfully completed at least 80% of survey items, with 73% of respondents from Europe, 12% from Australia, 7% from the United States, 2% from Israel, and 6% from other countries. Results: Half of all respondents and 27% of those with a previous melanoma reported at least one severe sunburn during the previous 12 months. The strongest factors associated with sun protection behavior were perceived barriers to protection (β = −0.44/β = −0.37), and respondents who reported a positive attitude toward suntans were less likely to protect (β = −0.16/β = −0.14). Reported use of protective clothing and shade, as well as avoidance of midday sun exposure, were more strongly related to reduced risk of sunburn than sunscreen use. Conclusions: Despite widespread dissemination of public health messages about the importance of sun protection, a substantial proportion of this international sample, including respondents with a previous melanoma, reported inadequate sun protection behaviors resulting in severe sunburn. Impact: Future strategies to decrease sunburn should target the practical, social, and psychological barriers associated with nonuptake of sun protection. Cancer Epidemiol Biomarkers Prev; 19(9); 2199–210. ©2010 AACR.
Archives of Dermatology | 2009
Francisco Cuellar; Antonio Vilalta; Susana Puig; Josep Palou; Gabriel Salerni
T HE LESIONS SHOWN IN THIS ARTICLE ARE from the upper lip of an 85-year-old woman (Figure 1, inset), the malar of a 67-year-old man (Figure 2, inset), and the forehead of a 56-year-old man (Figure 3, inset). They correspond to actinic keratosis (AK) (case 1), lichenoid AK (case 2), and squamous cell carcinoma that developed on an AK (case 3). Polarized contact dermoscopy of all 3 lesions revealed a pattern called a rosette sign (Figures 1-3, arrows), a term coined by Lester Cowell, MD, and is characterized by 4 white points arranged as a 4-leaf clover (Figure 4) mainly localized inside the follicular openings. Histologically, the rosette sign may correspond to changes of orthokeratosis and parakeratosis (flag sign) (Figure 5 [case shown in Figure 3]). It is occasionally seen in AK and related conditions and could help in their diagnosis. It does not appear in nonpolarized contact dermoscopic images and may therefore represent a tissue and polarized light phenomenon.
International Journal of Cancer | 2007
Alisa M. Goldstein; Valérie Chaudru; Paola Ghiorzo; Celia Badenas; Josep Malvehy; Lorenza Pastorino; Karine Laud; Benjamin Hulley; Marie-Françoise Avril; Joan Anton Puig-Butille; Annie Minière; Rosa M. Martí; Agnès Chompret; Francisco Cuellar; Isabel Kolm; Montserrat Milà; Margaret A. Tucker; Florence Demenais; Giovanna Bianchi-Scarrà; Susana Puig; Brigitte Bressac de-Paillerets
The G101W founder mutation is the most common CDKN2A mutation in Italy, Spain, and France. As the background of modifying genes, environmental exposures, and sun behavior vary across countries, studying G101W carriers from distinct countries offers a unique opportunity to evaluate possible modifying factors in melanoma development. We evaluated 76 G101W cases and 59 carrier controls from France, Italy, Spain, and the United States. Hair color and dysplastic nevi distributions differed significantly in cases and controls across the 4 study groups. Cases also varied significantly for eye color, freckling, and nevi. The distribution of MC1R variants in cases differed significantly across study groups because 12% of Italian melanoma patients had ≥2 MC1R variants vs. >50% for the other case groups. Several MC1R covariates showed significant associations with melanoma risk in all groups combined and in the American, French, and Spanish samples; no significant findings were observed in the Italian sample. In multiple‐case families, the number and type of MC1R variants varied significantly between multiple‐primary‐melanoma and single‐primary‐melanoma patients from the 4 groups; there was also a significant decrease in median age at melanoma diagnosis as the number or type of MC1R variants increased. The variation in the effects of the cutaneous phenotypic and MC1R factors across the study sample suggests that these factors differentially contribute to development of melanoma even on a common genetic background of a germline CDKN2A mutation. Differences in melanoma risk across geographic regions justify the need for individual studies in each country before counseling should be considered.
British Journal of Dermatology | 2009
Francisco Cuellar; Susana Puig; Isabel Kolm; Joan-Anton Puig-Butille; Pedro Zaballos; R.M. Martí‐Laborda; Celia Badenas; J. Malvehy
Background The presence of at least one MC1R gene variant is associated with a reduction in age at melanoma diagnosis in families with CDKN2A mutations.
International Journal of Cancer | 2003
Ramón Vilella; Daniel Benitez; Jordi Milà; Antoni Vilalta; Ramón Rull; Francisco Cuellar; Carles Conill; Sergi Vidal-Sicart; Josep Costa; Eva Yachi; Josep Palou; Josep Malvehy; Susana Puig; Rosa M. Martí; Begoña Mellado; Teresa Castel
Unresectable metastatic melanoma has no elective treatment. Neither chemotherapy, intravenous IL‐2 nor biochemotherapy clearly improves the overall survival. Recent assays with therapeutic vaccines have been recently yielded promising results. Here, we describe the application, clinical tolerance and antitumoural activity of a heterologous polyvalent melanoma whole cell vaccine in patients with metastatic melanoma. Twenty‐eight AJCC stage III/IV melanoma patients with progressive unresectable metastatic disease were treated with our heterologous polyvalent melanoma whole cell vaccine between July 1, 1998 and July 1, 2002. All patients had already been unsuccessfully treated with high doses of IFN‐α2 and/or polychemotherapy and/or biochemotherapy and/or perfusion of extremities, or could not receive other treatments due to their age or underlying illness. Twenty‐three were assessable. The vaccine was constituted by 10 melanoma cell lines, derived from primary, lymph node and metastatic melanomas. Prior to intradermal inoculation, the cells were irradiated and mixed with BCG, and 50% were treated with DNFB. After a median follow‐up of 19 months, 26% of patients responded: 3 CR (18, 16+, and 26+ months), 2 PR (8 and 22 months) and 1 MR (36+ months). The median survival of the whole group was 20.2 months. None of the 28 patients initially included in the study presented significant toxicity. This vaccination program had specific antitumoural activity in advanced metastatic melanoma patients and was well tolerated. The clinical responses and the median survival of our group of patients, together with the low toxicity of our polyvalent vaccine, suggest that this approach could be applied to earlier metastatic melanoma patients.
Archives of Dermatology | 2008
Francisco Cuellar; Antonio Vilalta; Susana Puig; Josep Palou; Pedro Zaballos; Josep Malvehy
Francisco Cuellar, MD; Antonio Vilalta, MD; Susana Puig, MD, PhD; Josep Palou, MD; Pedro Zaballos, MD; Josep Malvehy, MD, PhD; Unidad de Dermatologia Quirurgica, Barcelona (Drs Cuellar and Vilalta), Hospital Clinic, Institut de Investigacions Biomediques Cientifiques Agusti Pi I Suryer, Barcelona (Drs Cuellar, Vilalta, Palou, Puig, and Malvehy), and Hospital de Sant Pau i Santa Tecla, Tarragona (Dr Zaballos), Spain
British Journal of Dermatology | 2009
Alejandra Larre Borges; Francisco Cuellar; Joan Anton Puig-Butille; M. Scarone; L. Delgado; Celia Badenas; Montserrat Milà; J. Malvehy; V. Barquet; J. Núñez; M. Laporte; G. Fernández; P. Levrero; M. Martínez-Asuaga; Susana Puig
Background Familial melanoma, a cluster of several cases within a single family, accounts for approximately 10% of cases of melanoma. Hereditary melanoma is defined as two or more first‐degree relatives having melanoma. A member of a melanoma‐prone family has a 35–70‐fold increased relative risk of developing a melanoma. Genetic susceptibility is linked to the major susceptibility genes CDKN2A and CDK4, and the minor susceptibility gene MC1R.
Dermatology | 2010
Pedro Zaballos; Elisabeth Salsench; Patricia Serrano; Francisco Cuellar; Susana Puig; Josep Malvehy
Background: Lichenoid keratosis (LK) is a well-described entity that has been proposed to represent a regressive response to a pre-existent epidermal lesion. Aims: To evaluate the natural evolution of a series of cases showing the intermediate stage of the regression of seborrheic keratosis in LK using sequential dermoscopy imaging over time. Material and Methods: A series of lesions with dermoscopic areas of seborrheic keratosis and LK in the same tumor were consecutively collected for over 3 years at the Dermatology Department of the Hospital de Sant Pau i Santa Tecla, Tarragona, Spain. Sequential dermoscopic images of each case were collected quarterly for 1 year. At the end of the follow-up, all the lesions were biopsied. Results: A total of 22 cases were collected. At the end of the follow-up, the LK part increased in all the lesions. In 11 cases (50%), the seborrheic keratosis part disappeared completely, and in another 5 cases (22.7%), seborrheic keratosis comprised only 10% of the remaining area. Conclusions: These dermoscopic study findings support the proposal that LK represents a regressive response to a pre-existent epidermal lesion, in this case seborrheic keratosis.